Literature DB >> 16142411

The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo.

Wen G Jiang1, Gaynor Davies, Tracey A Martin, Christian Parr, Gareth Watkins, Robert E Mansel, Malcolm D Mason.   

Abstract

Lymphangiogenesis is key to the lymphatic spread of cancer cells. The current study examined the potential effect of hepatocyte growth factor (HGF), a factor known to have strong biological effects on endothelial cells, on the lymphangiogenic function of endothelial cells and the formation of lymphatic vessels using both in vitro and in vivo models. Human endothelial cells that have lymphatic characteristics, human prostate and breast cancer cells PC-3 and MDA MB 231, were used. Expression of lymphatic markers, podoplanin, Prox-1, vascular endothelial growth factor receptor 3 (VEGF-R3) and LYVE-1 was determined using reverse transcription polymerase reaction and quantitative PCR. In nude mice prostate and breast xenograft tumour models, either HGF or an HGF-producing fibroblast cell line MRC-5 was given with or without the HGF antagonist, NK4. The lymphangiogenic marker and lymphatic vessels in tumour tissues were also assessed using quantitative PCR and immunohistochemistry, respectively. In the mice tumour models, infusion of rhHGF significantly increased the levels of podoplanin and LYVE-1 in the tumour (p=0.05 for podoplanin and p<0.05 for LYVE-1 vs. without HGF in the prostate tumour model, p<0.05 for podoplanin and p<0.01 for LYVE-1 vs. without HGF for the breast tumour model; p<0.05 for podoplanin and p<0.01 for LYVE-1 vs. without HGF in the breast tumour model). The increased level of LYVE-1 transcript was supported by an increase in the number of LYVE-1-positive lymphatic vessels in tumours, using immunohistochemical analysis. Co-injection of MRC5 cells also increased the levels of LYVE-1 and number of LYVE-1-positive vessels in tumour tissues. The effects of HGF and MRC5 were significantly reduced by the HGF antagonist, NK4. In the in vitro models, rhHGF significantly increased the level of both podoplanin and LYVE-1, as shown by quantitative PCR analysis. Hepatocyte growth factor has potential lymphangiogenic activities, and this may have important implications in the nodal spread of cancer cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16142411

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  14 in total

1.  Assessment of vascularity in glioblastoma and its implications on patient outcomes.

Authors:  Ben G McGahan; Beth K Neilsen; David L Kelly; Rodney D McComb; S A Jaffar Kazmi; Matt L White; Yan Zhang; Michele R Aizenberg
Journal:  J Neurooncol       Date:  2017-01-19       Impact factor: 4.130

2.  Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis.

Authors:  Robert B Rebhun; Robert R Langley; Kenji Yokoi; Dominic Fan; Jeffrey E Gershenwald; Isaiah J Fidler
Journal:  Neoplasia       Date:  2006-09       Impact factor: 5.715

Review 3.  The lymphatic vasculature: An active and dynamic player in cancer progression.

Authors:  Sara Rezzola; Elena C Sigmund; Cornelia Halin; Roberto Ronca
Journal:  Med Res Rev       Date:  2021-09-05       Impact factor: 12.388

4.  N-WASP is a putative tumour suppressor in breast cancer cells, in vitro and in vivo, and is associated with clinical outcome in patients with breast cancer.

Authors:  Tracey A Martin; Gordon Pereira; Gareth Watkins; Robert E Mansel; Wen G Jiang
Journal:  Clin Exp Metastasis       Date:  2007-11-06       Impact factor: 5.150

Review 5.  Potential therapeutic strategies for lymphatic metastasis.

Authors:  Bernadette M M Zwaans; Diane R Bielenberg
Journal:  Microvasc Res       Date:  2007-09-19       Impact factor: 3.514

6.  Modulating metastasis by a lymphangiogenic switch in prostate cancer.

Authors:  Ebba Brakenhielm; Jeremy B Burton; Mai Johnson; Nelson Chavarria; Kouki Morizono; Irvin Chen; Kari Alitalo; Lily Wu
Journal:  Int J Cancer       Date:  2007-11-15       Impact factor: 7.396

7.  First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours.

Authors:  I Van der Auwera; Y Cao; J C Tille; M S Pepper; D G Jackson; S B Fox; A L Harris; L Y Dirix; P B Vermeulen
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640

8.  Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3.

Authors:  Yunling Xu; Li Yuan; Judy Mak; Luc Pardanaud; Maresa Caunt; Ian Kasman; Bruno Larrivée; Raquel Del Toro; Steven Suchting; Alexander Medvinsky; Jillian Silva; Jian Yang; Jean-Léon Thomas; Alexander W Koch; Kari Alitalo; Anne Eichmann; Anil Bagri
Journal:  J Cell Biol       Date:  2010-01-11       Impact factor: 10.539

9.  Hepatocyte growth factor and the hepatocyte growth factor receptor signalling complex as targets in cancer therapies.

Authors:  W G Jiang
Journal:  Curr Oncol       Date:  2007-04       Impact factor: 3.677

10.  HOXA13 Is essential for placental vascular patterning and labyrinth endothelial specification.

Authors:  Carley A E Shaut; Douglas R Keene; Lise K Sorensen; Dean Y Li; H Scott Stadler
Journal:  PLoS Genet       Date:  2008-05-16       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.